Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | PPARD | Q03181 | 1/20 | 1.00 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 1.00 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 1.00 |
| ▸ | ZDHHC7 | Q9NXF8 | 2/20 | 0.62 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.59 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.53 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.48 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.48 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.46 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10595854 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL11595308 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL9096771 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL817063 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL3954525 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL23829555 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL337934 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL8572016 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL2718855 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 | |
| SCHEMBL2721068 | 1.00 | LCK (1.00) | LCKPPARDZDHHC20ZDHHC2ZDHHC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-09-10 | — | — | US | disclosed |
| US-7566808-B2 | Management of ophthalmologic disorders, including macular degeneration | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2009-07-28 | — | — | US | disclosed |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-10-30 | — | — | US | disclosed |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-07-24 | — | — | US | disclosed |
| EP-1919858-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | The President and Fellows of Harvard College (US) | 2008-05-14 | — | — | EP | disclosed |
| WO-2007019503-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-02-15 | — | — | WO | disclosed |
| EP-1722766-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-11-22 | — | — | EP | disclosed |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-03-30 | — | — | US | disclosed |
| WO-2005079774-A2 | MANAGEMENT OF OPHTHALMOLOGIC DISORDERS, INCLUDING MACULAR DEGENERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227649-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | LCK 4666/4885PPARD 1205/4885ZDHHC20 3734/4885 |
| US-20080176952-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | ALDH1A2, PDE6C, PDE6A | LCK 4619/4885PPARD 1265/4885ZDHHC20 3667/4885 |
| US-20060069078-A1 | Management of ophthalmologic disorders, including macular degeneration | ALDH1A2, PDE6C, PDE6B | LCK 4682/4885PPARD 919/4885ZDHHC20 2866/4885 |
| US-20080269324-A1 | Management of Ophthalmologic Disorders, Including Macular Degeneration | PDE6C, PDE6A, ALDH1A2 | LCK 4534/4885PPARD 1316/4885ZDHHC20 4096/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.